Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

ovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-GCGRRx and ISIS-GCCRRx for the treatment of type 2 diabetes.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other document
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... inaugural Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 ... in New York . A live ... . A replay will be available approximately one hour after ...
(Date:7/1/2015)... 2015 Lupin , ... Total Number of MPP Sub-licensees to Fourteen Companies   ... announced the rapid expansion of its network of generic manufacturers ... to develop MPP-licensed antiretrovirals (ARVs). New companies Lupin and Strides ... new HIV medicine the MPP licensed from ViiV Healthcare two ...
(Date:7/1/2015)... SAN DIEGO , July 1, 2015  AVACEN, Inc. ... a second AVACEN patent covering the medical technology platform supporting ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... The apparatus and methods patent no. 9,066,781 - Methods And ... devices manufactured by AVACEN and specific methods of use, referred ...
Breaking Medicine Technology:MEI Pharma to Present at Cantor Fitzgerald Healthcare Conference 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3AVACEN Medical Patent Issued 2
(Date:7/1/2015)... ... July 01, 2015 , ... The ... Levaquin ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According ... Virginia on June 26th, the Court rejected the Plaintiff’s assertion that one ...
(Date:7/1/2015)... ... July 01, 2015 , ... Ormco Corporation, ... that its fifth annual Smile for a Lifetime Foundation (S4L) fundraising event held ... In addition to supporting S4L in its mission to provide free quality orthodontic ...
(Date:7/1/2015)... ... 01, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . Set for March 6th - 8th, the 2016 meeting will be ... basic training and fundamentals of nasal surgery through the most modern advancements and updates ...
(Date:7/1/2015)... Tenn. (PRWEB) , ... July 01, 2015 , ... The ... held rain or shine Saturday, July 11, 2015, at 6 p.m. in Pugh Bourne ... free and includes pony rides, a petting zoo, an Elvis impersonator, a silent auction ...
(Date:7/1/2015)... ... July 01, 2015 , ... Trevor L. Williams, DMD holds a ... continued at USF earning a Master’s degree in Microbiology. He graduated from the University ... American Dental Association, the Florida Dental Association and the Academy of General Dentistry. Dr. ...
Breaking Medicine News(10 mins):Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Trevor L. Williams, D.M.D. Joins Enlow & Vance Dental Partners in Tampa, Florida 2
... WASHINGTON, July 24 Yesterday, the U.S. House ... (R-IN) which prohibits HHS (Health and Human Services) funding for programs ... blood-borne pathogens such as HIV and hepatitis. The amendment reads as ... of the bill (before the short title), insert the following: Sec.___. ...
... , , , PITTSBURGH, ... to 28 nonprofit organizations in Pennsylvania to assist programs that ... Highmark,s Employee Volunteer Grant Program, which reinforces the company,s appreciation ... , , Highmark ...
... , , FT. MYERS, Fla., July ... leading provider of cancer genetics testing services announced today that it ... ABT ). The Agreement provides for Abbott to supply ... situ hybridization)-based test for the diagnosis of melanoma. In ...
... PITTSBURGH, July 24 Cardiorobotics, Inc., a medical ... wide range of surgical and interventional applications has closed on ... The round was led by Eagle Ventures and its co-investors, ... and affiliated investors. , , ...
... , , The Authority offers patients ... Safety Advisories for improved patient safety , ... Safety Authority supports "National Patient Safety Day," Saturday, July 25, which ... take an active role in their healthcare. , ...
... COLUMBIA, S.C., July 24 UCI Medical Affiliates, Inc. (Other ... Executive Vice-President of Finance, Chief Financial Officer, and Secretary of ... 23, 2009 in federal court to criminal charges for falsifying ... and Exchange Commission. On the eight reports that were ...
Cached Medicine News:Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 2Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 3Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 4Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 5Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 6Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 7Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 8Health News:Highmark Inc. Awards $14,000 to 28 Pennsylvania Nonprofit Organizations 9Health News:NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 2Health News:NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 3Health News:NeoGenomics Enters into Strategic Supply Agreement with Abbott for Development of a Melanoma Cancer Test 4Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 2Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 3Health News:Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery 4Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Pennsylvania Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... handheld oximeter has been converted to the ... now compatible with the entire line of ... Sensor and SoftCare Nonadhesive Sensors. The redesigned ... Nellcor's latest advanced signal processing technology, which ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: